Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Inclusion Criteria:

Histologically confirmed adenocarcinoma of the prostate
Progressive metastatic disease or stable metastatic disease with rising PSA
Previously treated with bilateral orchiectomy or other primary hormonal therapy with evidence of treatment failure
Patients who have not undergone bilateral orchiectomy must continue luteinizing hormone-releasing hormone (LHRH)-agonist therapy (e.g., leuprolide or goserelin) or LHRH antagonist therapy (e.g. abarelix) while receiving study treatment
Patients who did not have an orchiectomy must have a testosterone level < 50 ng/dL to confirm androgen suppression within the past 4 weeks
ECOG performance status 0-2
Adequate bone marrow function
Bilirubin =< 1.5 mg/dL
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal
Creatinine =< 2.0 mg/dL OR creatinine clearance >= 40 mL/min
Fertile patients must use effective contraception
A taxane-based regimen, mitoxantrone, or other cytotoxic chemotherapy regimen allowed provided there is evidence of disease progression
At least 4 weeks since prior chemotherapy or radiotherapy
At least 4 weeks since prior flutamide (6 weeks for bicalutamide or nilutamide) and there is continued evidence of disease progression
Disease progression after antiandrogen withdrawal must be confirmed by rising PSA after the required 4-6 week washout period (e.g., PSA level higher than the last PSA obtained while on antiandrogen therapy)
More than 4 weeks since prior estrogen, estrogen-like agents (e.g., PC-SPES, saw palmetto, or other herbal products that may contain phytoestrogens), or any other hormonal therapy (including megestrol, finasteride, ketoconazole, or systemic corticosteroids)
Concurrent bisphosphonates (e.g., pamidronate sodium or zoledronate) allowed provided the patient has been receiving the bisphosphonate for >= 4 weeks and there is evidence of disease progression

Exclusion Criteria:

Active angina pectoris
Known New York Heart Association class III-IV heart disease
Myocardial infarction within the past 6 months
Evidence of ventricular dysrhythmias or other unstable arrhythmia (rate-controlled atrial fibrillation is allowed if the patient is asymptomatic from a cardiac standpoint)
Peripheral neuropathy > grade 2
Other prior malignancy (excluding nonmelanomatous skin cancer treated with curative intent) unless the malignancy was treated with curative intent and the patient has been disease free for >= 5 years
Serious concurrent medical illness or active infection that would preclude study treatment - No concurrent strong inhibitors or inducers of CYP3A4
More than 2 prior chemotherapy regimens for hormone-refractory disease - Other concurrent investigational agents
Other concurrent anticancer therapy, including chemotherapy, gene therapy, biologic therapy, or immunotherapy
Concurrent palliative radiotherapy
Concurrent estrogen, estrogen-like agents, or any other hormonal therapy
Carcinomatous meningitis or brain metastases
Prior strontium chloride Sr 89, samarium 153 lexidronam pentasodium, or other radioisotopes
Concurrent therapeutic anticoagulation with warfarin (Unfractionated heparin [standard, low-dose, or adjusted dose] or low molecular weight heparin allowed